{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:56Z","timestamp":1787841296191,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed\/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.<\/jats:p>","DOI":"10.56875\/2589-0646.1039","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T11:29:57Z","timestamp":1686655797000},"page":"346-350","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia"],"prefix":"10.4103","volume":"16","author":[{"given":"Guru Subramanian","family":"Guru Murthy","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"10129","key":"R1-20241211","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"R2-20241211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J Clin"},{"key":"R3-20241211","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest"},{"issue":"4","key":"R4-20241211","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"R5-20241211","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"R6-20241211","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"R7-20241211","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"10232","key":"R8-20241211","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"R9-20241211","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"9","key":"R10-20241211","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"9","key":"R11-20241211","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"R12-20241211","first-page":"JCO2101181","article-title":"Minimal Residual Disease Dynamics after Venetoclax- Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"R13-20241211","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"11","key":"R14-20241211","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.2019003451","article-title":"High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia","volume":"135","author":"Al-Sawaf","year":"2020","journal-title":"Blood"},{"issue":"20","key":"R15-20241211","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib- based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"R16-20241211","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am J Hematol"},{"key":"R17-20241211","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"R18-20241211","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"R19-20241211","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"R20-20241211","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/ajh.26260","article-title":"Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial","volume":"96","author":"Al-Sawaf","year":"2021","journal-title":"Am J Hematol"},{"issue":"22","key":"R21-20241211","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1182\/blood.V128.22.5928.5928","article-title":"Real-world health care utilization and costs among patients newly initiating systemic therapy for chronic lymphocytic leukemia (CLL) in the United States","volume":"128","author":"Matasar","year":"2016","journal-title":"Blood"},{"issue":"6","key":"R22-20241211","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/PPO.0000000000000411","article-title":"Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia","volume":"25","author":"Harkins","year":"2019","journal-title":"Cancer J"},{"issue":"9","key":"R23-20241211","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40273-020-00919-1","article-title":"Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States","volume":"38","author":"Cho","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"R24-20241211","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"34","key":"R25-20241211","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"R26-20241211","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Non- randomized Phase 2 Trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAM A Oncol"},{"issue":"12","key":"R27-20241211","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"R28-20241211","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:54Z","timestamp":1787838534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1039","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}